Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Exiting Two Therapeutic Areas | Main | The Past Twenty Years of Drug Development, Via the Literature »

November 8, 2013

The Other Shoe Drops at Ariad

Email This Entry

Posted by Derek

Ever since Iclusig (ponatinib) (note: fixed that name as an update) ran into trouble with blood-cloting side effects, Ariad has had a huge uncertain cloud blocking out its sunlight. Now that the FDA has told them to take the drug off the market completely, it was clear what was going to happen. Happen it has: the company is laying off a large part of its workforce.

It's very much in doubt whether Iclusig will ever come back. Update: in Europe, the EMA has now said that Iclusig can remain on the market "with increased caution").And if it doesn't, it's very much in doubt whether Ariad will, or how long that might take. There's a large, mostly-completed building around the corner from me covered in blue-green glass that was going to be the home of a larger, more solvent Ariad, and no one knows what's going to happen to that, either. It's a rough business.

Update: turns out the blue-green glass one was going to be Aveo, which cratered earlier this year. Who's going to occupy that, one wonders? Ariad's is the less-complete large framework going up across from the (incongruous) Mormon church. That's a pretty large building, or will be, and you wonder who will end up in there. There are so many biopharma construction sites in this town that you need a guidebook.

Comments (23) + TrackBacks (0) | Category: Business and Markets | Cancer | Regulatory Affairs


COMMENTS

1. Anonymous on November 8, 2013 8:31 AM writes...

Derek,
The name is Iclusig (not Inclusig)

Permalink to Comment

2. bluchem on November 8, 2013 8:42 AM writes...

Derrick, Ariad's buildings are nowhere complete, they are the one's around the corner from you that are nothing more than steel beams and a big red crane. That blu-green glass building was so supposed to house Aveo, well we know what happened to them also.

Permalink to Comment

3. AndrewD on November 8, 2013 10:34 AM writes...

Derrick
Two companies that were building shiny new buildings collapse:- does this suggest a trend or a cause?

Permalink to Comment

4. qetzal on November 8, 2013 10:53 AM writes...

There's still an "Inclusig" left in the first sentence of paragraph 2.

Permalink to Comment

5. Org Lett Reader on November 8, 2013 11:06 AM writes...

Commenters,
The name is Derek (not Derrick).

Permalink to Comment

6. RB Woodweird on November 8, 2013 11:19 AM writes...

Let's recap, shall we?

Job postings at Ariad.
Applied.
Boston Globe: Cratering.

Job postings for Vertex.
Applied.
Boston Globe: Sudden amputation.

Job posting for Immunogen.
Applied.
Boston Globe: Gloom and doom.

New money-making scheme hatched.
Send me money and I won't send a resume to your company.

Permalink to Comment

7. Anonymous on November 8, 2013 11:37 AM writes...

The trick is to work in HR: They are always busy writing job ads and screening CVs for positions they don't, or won't need.

Permalink to Comment

8. Anon on November 8, 2013 11:48 AM writes...

@RB Woodweird - a second money-making scheme would be to rent out your services to short-sellers.

Permalink to Comment

9. Anonymous on November 8, 2013 12:06 PM writes...

How this is executed is very interesting. The FDA require removal from the US market and 40% of US-based staff are laid off, likely to claim unemployment benefits once severance expires. The EU requires only a black box warning and not a single EU staffer is laid off.

On the surface this seems vengeful, but I am not aware of the internal workings over at Ariad (maybe EU operations have some unique value).

Permalink to Comment

10. Anonymous on November 8, 2013 12:18 PM writes...

@9: How is it vengeful? There is now no need for a US sales force, but still a need for an EU one...

Permalink to Comment

11. Anonymous on November 8, 2013 12:53 PM writes...

@10: This would make sense, were it not for US layoffs to include staff in all major departments, including R&D. See link below and the Ariad press release.

http://www.fiercebiotech.com/story/ariad-canning-40-us-workers-troubled-iclusig-gathers-dust/2013-11-07

Permalink to Comment

12. watcher on November 8, 2013 1:00 PM writes...

Dl: not to many shoes left.....

Perhaps, biotechs should wait for money to flow into the bank instead of planning big new labs, infrastuctures when there is still only the hope of the waterfall of income.

Permalink to Comment

13. Anonymous on November 8, 2013 1:10 PM writes...

@11: R&D usually has to be cut in the same place where sales are cut to benefit from an R&D tax shield.

Permalink to Comment

14. Canageek on November 8, 2013 2:08 PM writes...

6. RB Woodweird:

Did Coop position at Merck Montreal. Merck Montreal closed that summer.

Did summer job at Atomic Energy of Canada Ltd.
AECL privatized with massive layoffs the following year.

Since then I've stuck with Academic positions; half the pay, but at least if I can find a job I won't lose it the second I get comfortable!

Permalink to Comment

15. Anonymous on November 8, 2013 2:49 PM writes...

@14: I hope that's not a cause-effect relationship, otherwise stay away from my company!

Permalink to Comment

16. The Fat Layer on November 8, 2013 3:01 PM writes...

Ariad is axing 40% of the workforce in the US.

See http://www.biospace.com/News/ariad-pharmaceuticals-inc-chops-40-percent-of/314965/Source=TopBreaking

Tough, tough, tough all way around...

Permalink to Comment

17. Ted on November 8, 2013 3:02 PM writes...

Started at U - 1 year later --> became PU. I left for D(my only voluntary leave of a job). PU became Ph became Pf --> Closed.

Joined D. Immediately became DD, a subsidiary of Ch. Ch became Ct. Chemistry laid off. Site closed.

Joined Cy. Chemistry laid off. Site closed.

Joined I. Everyone laid off. Site closed.

Joined S-R. Everyone laid off. Site closed.

Now I work for a company many people hate. I tell them I'm working on their behalf...

-t

Permalink to Comment

18. The Fat Layer on November 8, 2013 3:07 PM writes...

@9: "likely to claim unemployment benefits once severance expires"

I don't know how things work in MA, but in some states if you are laid off and receive a severance package you don't get benefits for some time or at all.

Permalink to Comment

19. anomalous on November 8, 2013 3:19 PM writes...

@9 and @18: I can tell you from experience that in MA and IL you can start taking unemployment benefits as soon as you're layed (laid?) off, whether or not you get a severance package. For other states, I can't say.

Permalink to Comment

20. Lu on November 8, 2013 4:27 PM writes...

'this the season...
Sorry to everyone affected.

Permalink to Comment

21. Just askin' on November 8, 2013 7:14 PM writes...

So, contrary to what the Boston Globe has published recently, will there be an end in sight for the Boston Biotech Bubble?

Permalink to Comment

22. R. H. B. on November 8, 2013 7:48 PM writes...

Grim week (Novartis Horsham and Emeryville, BMS, Shire, Ariad). Although only two of these are in the traditional chemistry-led drug discovery heartlands of New Jersey and provincial Old England, the dismantling of the heartlands is now almost done. Farewell to the quietish places the named inventors of successful drugs called home.

Anyone out there come across a drug discovery Mercator projection, with pins showing where approved drugs were first synthesised? Time consuming to compile, but should be relatively straightforward to get to by looking up geographical locations of assignees of the first published patent applications that exemplified or claimed the compounds. Use whatever criterion you like (All Time Top 50, 2012 Best Sellers, 2008-2013 New Releases, etc, etc). No doubt the legacy maps would come out pretty similar, with a highish concentration of pins in the heartlands.

Now we're at the outset of a brave (or rash) experiment. Novartis and BMS plan to partly compensate by shifting scientists to Boston Mass. Out of the heartlands and into the biology-led hubs/ecosystems/hotspots (delete whichever two you're most bored with hearing). Out of boring New Jersey and provincial Old England, into trendy Boston Mass and Cambridge UK. Anyone out there tell us how many pins these hubs/ecosystems/hotspots boast on legacy drug discovery maps..?

Biggest Q of All - What will the maps look like in 2033? Of course the maps won't just reflect geography, but will be about any number of factors we're fuzzily aware of now or that come to matter in the future. So come on you futurologists, get your pins out and get predicting - as for me, I'll soon be on the sidelines, but hoping to spectate long enough to see how it plays out...

Permalink to Comment

23. @KayakPhilip on November 9, 2013 11:23 PM writes...

Did they not know about Shiny Building Syndrome? Neurocrine, Idec (San Diego?). Arena, now Vertex, Ariad and Aveo.

(Assuming there were new jobs to be found) I'd start looking around as soon as my company announced plans for a new building/campus

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
XKCD on Protein Folding
The 2014 Chemistry Nobel: Beating the Diffraction Limit
German Pharma, Or What's Left of It
Sunesis Fails with Vosaroxin
A New Way to Estimate a Compound's Chances?
Meinwald Honored
Molecular Biology Turns Into Chemistry
Speaking at Northeastern